Stromal fibroblasts in cancer: a novel tumor-promoting cell type - PubMed
- ️Invalid Date
Review
. 2006 Aug;5(15):1597-601.
doi: 10.4161/cc.5.15.3112. Epub 2006 Aug 1.
Affiliations
- PMID: 16880743
- DOI: 10.4161/cc.5.15.3112
Review
Stromal fibroblasts in cancer: a novel tumor-promoting cell type
Akira Orimo et al. Cell Cycle. 2006 Aug.
Abstract
Tumors are highly complex tissues composed of neoplastic cells and, in the case of carcinomas, stromal cell compartments containing a variety of mesenchymal cells, notably fibroblasts, myofibroblasts, endothelial cells, pericytes, and a variety of inflammatory cells associated with the immune system. Fibroblasts and myofibroblasts often represent the majority of the stromal cells within various types of human carcinomas, yet the specific contributions of these cells to tumor growth are poorly understood. Recent work has demonstrated that stromal fibroblast fractions, named carcinoma-associated fibroblasts (CAFs), that have been extracted from a number of invasive human breast carcinomas are more competent to promote the growth of mammary carcinoma cells and to enhance tumor angiogenesis than are comparable cells derived from outside of these tumor masses. CAFs include large populations of myofibroblasts that secrete elevated levels of stromal cell-derived factor 1 (SDF-1), also called CXCL12, which plays a central role in the promotion of tumor growth and angiogenesis; CAF-derived SDF-1 not only stimulates carcinoma cell growth directly through the CXCR4 receptor displayed on tumor cells but also serves to recruit endothelial progenitor cells (EPCs) into tumors, thereby furthering neoangiogenesis. In this review, we highlight the importance of this SDF-1-CXCR4 signaling pathway in the tumor microenvironment and discuss the mechanisms by which stromal fibroblasts within mammary carcinomas enhance tumor growth.
Similar articles
-
Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Orimo A, et al. Cell. 2005 May 6;121(3):335-48. doi: 10.1016/j.cell.2005.02.034. Cell. 2005. PMID: 15882617
-
Huang M, Li Y, Zhang H, Nan F. Huang M, et al. J Exp Clin Cancer Res. 2010 Jun 22;29(1):80. doi: 10.1186/1756-9966-29-80. J Exp Clin Cancer Res. 2010. PMID: 20569497 Free PMC article.
-
Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, Onder TT, Wang ZC, Richardson AL, Weinberg RA, Orimo A. Kojima Y, et al. Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20009-14. doi: 10.1073/pnas.1013805107. Epub 2010 Nov 1. Proc Natl Acad Sci U S A. 2010. PMID: 21041659 Free PMC article.
-
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.
Burger JA, Kipps TJ. Burger JA, et al. Blood. 2006 Mar 1;107(5):1761-7. doi: 10.1182/blood-2005-08-3182. Epub 2005 Nov 3. Blood. 2006. PMID: 16269611 Review.
-
Activation of fibroblasts in cancer stroma.
Räsänen K, Vaheri A. Räsänen K, et al. Exp Cell Res. 2010 Oct 15;316(17):2713-22. doi: 10.1016/j.yexcr.2010.04.032. Epub 2010 May 6. Exp Cell Res. 2010. PMID: 20451516 Review.
Cited by
-
Herrera M, Herrera A, Domínguez G, Silva J, García V, García JM, Gómez I, Soldevilla B, Muñoz C, Provencio M, Campos-Martin Y, García de Herreros A, Casal I, Bonilla F, Peña C. Herrera M, et al. Cancer Sci. 2013 Apr;104(4):437-44. doi: 10.1111/cas.12096. Epub 2013 Feb 21. Cancer Sci. 2013. PMID: 23298232 Free PMC article.
-
Suppression of CXCL-1 Could Restore Necroptotic Pathway in Chronic Lymphocytic Leukemia.
Xu Z, Sun Y, Wei Z, Jiang J, Xu J, Liu P. Xu Z, et al. Onco Targets Ther. 2020 Jul 16;13:6917-6925. doi: 10.2147/OTT.S256993. eCollection 2020. Onco Targets Ther. 2020. PMID: 32764983 Free PMC article.
-
Liu ZJ, Li Y, Tan Y, Xiao M, Zhang J, Radtke F, Velazquez OC. Liu ZJ, et al. PLoS One. 2012;7(6):e38811. doi: 10.1371/journal.pone.0038811. Epub 2012 Jun 8. PLoS One. 2012. PMID: 22715413 Free PMC article.
-
Impact of Nintedanib and Anti-Angiogenic Agents on Uveal Melanoma Cell Behavior.
Pawlik VE, Sonntag SR, Grisanti S, Tura A, Kakkassery V, Ranjbar M. Pawlik VE, et al. Invest Ophthalmol Vis Sci. 2024 Feb 1;65(2):30. doi: 10.1167/iovs.65.2.30. Invest Ophthalmol Vis Sci. 2024. PMID: 38381412 Free PMC article.
-
Huang Y, Feng Q, Jiang H, Zhou W, Chen J, Gao J, Wang K, Wan X, Yu Y. Huang Y, et al. Int J Nanomedicine. 2020 Jun 25;15:4625-4637. doi: 10.2147/IJN.S252074. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32636622 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources